Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMERA: Reducing and stopping methotrexate in rheumatoid arthritis patients on certolizumab pegol
jRCTs041200048Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Jan 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Randomised, open-label trial of certolizumab pegol in rheumatoid arthritis (RA) (2 arms), sponsored by Astellas Pharma. Started Jan 2021; status: active, not recruiting.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCTs041200048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041200048.